Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS041783, AG063520)
Article History
Received: 17 October 2022
Accepted: 20 January 2023
First Online: 30 January 2023
Declarations
:
: All animal use was approved by the IACUC committee of Harvard Medical School and Brigham and Women's Hospital in accordance with the USDA Animal Welfare Act and PHS Policy on Humane Care and Use of Laboratory Animals.
: Not applicable.
: J.S. has financial interests in iNeuro Therapeutics and Paros Bio, which develop therapies for Alzheimer’s disease. J.S.’s interests are managed by Mass General Brigham in accordance with the institutional competing interests policies.